Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 10 | $0.57 | $0.75 | $0.67 |
Q2 2025 | 11 | $0.55 | $0.62 | $0.58 |
Q3 2025 | 10 | $0.63 | $0.82 | $0.71 |
Q4 2025 | 10 | $0.62 | $0.81 | $0.71 |
Q1 2026 | 8 | $0.69 | $0.76 | $0.72 |
Q2 2026 | 8 | $0.64 | $0.70 | $0.67 |
Q3 2026 | 8 | $0.87 | $0.97 | $0.92 |
Q4 2026 | 8 | $0.75 | $0.83 | $0.79 |
Pfizer Inc. last posted its earnings results on Tuesday, August 5th, 2025. The company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.2. The company had revenue of 14.65 B for the quarter and had revenue of 63.63 B for the year. Pfizer Inc. has generated $1 earnings per share over the last year ($1.409 diluted earnings per share) and currently has a price-to-earnings ratio of 13.21. Pfizer Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 4th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
08/05/2025 | Q2 2025 | $0.58 | $0.51 | -0.07 | $13.56 B | $14.65 B |
03/29/2025 | Q1 2025 | N/A | $0.52 | N/A | $13.92 B | $13.72 B |
02/27/2025 | Q4 2024 | N/A | $0.07 | N/A | N/A | $17.76 B |
11/04/2024 | Q3 2024 | N/A | $0.79 | N/A | $14.92 B | $17.70 B |
08/05/2024 | Q2 2024 | N/A | $0.00 | N/A | N/A | $13.28 B |
05/08/2024 | Q1 2024 | N/A | $0.55 | N/A | N/A | $14.88 B |
02/22/2024 | Q4 2023 | N/A | -$0.60 | N/A | N/A | $14.57 B |
11/08/2023 | Q3 2023 | N/A | -$0.42 | N/A | N/A | $13.49 B |
08/09/2023 | Q2 2023 | N/A | $0.41 | N/A | N/A | $13.01 B |
05/10/2023 | Q1 2023 | N/A | $0.98 | N/A | N/A | $18.49 B |
02/23/2023 | Q4 2022 | N/A | $0.89 | N/A | N/A | $24.29 B |
11/09/2022 | Q3 2022 | N/A | $1.54 | N/A | N/A | $22.64 B |
08/10/2022 | Q2 2022 | N/A | $1.77 | N/A | N/A | $27.74 B |
05/11/2022 | Q1 2022 | N/A | $1.40 | N/A | N/A | $25.66 B |
02/24/2022 | Q4 2021 | N/A | $0.60 | N/A | $24.16 B | $23.84 B |
11/12/2021 | Q3 2021 | N/A | $1.45 | N/A | N/A | $24.04 B |
08/12/2021 | Q2 2021 | N/A | $1.04 | N/A | N/A | $18.90 B |
05/13/2021 | Q1 2021 | N/A | $0.87 | N/A | N/A | $14.52 B |
02/25/2021 | Q4 2020 | N/A | $0.15 | N/A | $11.67 B | $11.63 B |
11/05/2020 | Q3 2020 | N/A | $0.26 | N/A | N/A | $10.28 B |
Pfizer Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 4th, 2025 based offlast year's report dates.
In the previous quarter, Pfizer Inc. (:PFE) reported $0.78 earnings per share (EPS) to beat the analysts' consensus estimate of $0.58 by $0.2.
The conference call for Pfizer Inc.'s latest earnings report can be listened to online.
The conference call transcript for Pfizer Inc.'s latest earnings report can be read online.
Pfizer Inc. (:PFE) has a recorded annual revenue of $63.63 B.
Pfizer Inc. (:PFE) has a recorded net income of $8.02 B.Pfizer Inc. has generated $1.4179 earnings per share over the last four quarters.
Pfizer Inc. (:PFE) has a price-to-earnings ratio of 13.21 and price/earnings-to-growth ratio is 0.37.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED